Topics:

The AIDS Reader: AIDS and HIV News and Information

Optimal timing for Starting Antiretroviral Therapy in HIV-Infected Patients with Cryptococcal Meningitis

A recent study published in the New England Journal of Medicine examines the optimal timing of starting antiretroviral therapy in patients with cryptococcal meningitis. Details here.

Recent Content

A once daily MVC plus DRV/r regimen had an effective role in antiretroviral drug-pretreated individuals with controlled HIV infection in this trial. In an aging HIV-infected population, with increasing comorbidities, this combination could be a safer option than standard triple therapy. More here.

It now seems probable that most people with HCV infection can be cured—even if they are co-infected with HIV. But the "cost" of cure is expensive. This author concludes that many new regimens are cost effective and should not be withheld or made difficult to obtain by insurance companies and other payors.

Antiretroviral treatment does not appear to affect a woman's ability to become pregnant or to adversely affect fetal outcomes, according to this study.

Here: a quiz about treating oral candidiasis with an azole drug in an HIV-positive person.

This study demonstrates an added benefit to tenofovir-based preexposure prophylaxis regimens in preventing HSV-2.

A statistically significant association exists between efavirenz for initial HIV therapy and the risk suicidality. When this drug is given as a component of an antiretroviral drug regimen, patients should be monitored carefully for the possibility of deterioration of their depression or evidence of suicidal behavior.

Physicians who treat patients with cryptococcal meningitis in untreated AIDS patients should be aware that early initiation of antiretroviral therapy is associated with increased mortality.

  • Sandra McCoy PhD

    (AUDIO) Now that HIV testing is universally mandated, what are the best ways to reach into a community to find those who remain untested? In this brief recorded interview, the head of a study designed to test two approaches describes why either one is better than the status quo.

  • (AUDIO) In a brief podcast, the director of the University of North Carolina infectious diseases center ponders the implications of new HIV strains that lead to AIDS symptoms significantly faster than in the past. To him, the response is obvious. What troubles him is that not everyone seems to sense the urgency

  • (AUDIO) The past year has been revolutionary for HIV-positive patients, both in medical care and in policy. And more is in store for the coming year, according to Dr. Michael Horberg of Kaiser Permanente. Listen as the immediate past president of the HIV Medicine Association briefly reviews events of 2013 and forecasts 2014.

  • (AUDIO) Now that guidelines mandate testing all adults for HIV status, what are the best ways to convey the results of this important but often sensitive test? Listen as the co-director of Emory University's Center for AIDS Research offers insights for effective communication on this topic.

By clicking Accept, you agree to become a member of the UBM Medica Community.